发布时间:
2021
-
08
-
18
点击次数:
0
Positions：
Chairman and CEO
Company：
Inmagene Biopharmaceuticals
个人简介：
Dr. Jonathan Wang has over 30 years of healthcare and life sciences experience, spanning entrepreneurship, investment, research, and finance. Under the supervision of Eric Kandel, a Nobel Laureate, he obtained a Ph.D. in Neurobiology from Columbia University where he was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship. He also earned an MBA from Stanford University. Dr. Wang is the Chairman and CEO of Inmagene, a leading clinical-stage biotech company focused on immunology-related therapeutic areas. With wholly owned subsidiaries in San Diego, Shanghai, Hangzhou and Wuhan, the company has raised approximately $140M financing and is building a strong pipeline with over 10 drug candidates. The lead drug candidate, IMG-020, is about to enter global phase 2 or 3 trials for 5 autoimmune indications. Dr. Wang was a Partner at OrbiMed, the world’s largest healthcare-dedicated investment firm. He co-founded OrbiMed Asia where he led the establishment and management of $1.1B PE/VE funds. He was named one of the top 10 healthcare investors in China. He incubated Apollomics and Bridge (acquired), and served as Chairman at Apollomics and Angelalign. He is a HKEX Biotech Advisory Panel member and a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders. He has authored two philosophy of science books.